COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04801056

Nashat Gabrail, MD

Dongxu Sun, dsun@truebinding.com (PI email not reported)

2021-03-16

Withdrawn

RCT

Randomized

Parallel

Blind label

unclear

Treatment

inclusion criteria: willing and able to provide written informed consent prior to performing study procedures (or legally authorized representative able to provide consent on the patient's behalf). age ≥ 18 years a positive severe acute respiratory syndrome coronavirus (sars-cov-2) infection confirmed by polymerase chain reaction (pcr) test or an equivalent test ≤ 3 days before randomization patients with mild to moderate covid-19 experiencing any of the following symptoms: mild (without shortness of breath or dyspnea): fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms moderate: any symptom of mild illness, shortness of breath with excursion, clinically suggestive of moderate illness with covid-19, such as respiratory rate ≥ 20 breaths per minute, saturation of oxygen (spo2) > 93% on room air at sea level, heart rate ≥ 90 beats per minute at low risk for progressing to severe covid-19 and/or hospitalization. adequate organ function at screening as evidenced by: hemoglobin > 10.9 g/dl absolute neutrophil count (anc) > 1.0 × 10^9/l platelets > 125 × 10^9/l alanine aminotransferase (alt) or aspartate aminotransferase (ast) < 1.25 × upper limit of normal (uln) creatinine clearance > 90 ml/min using the cockcroft-gault formula for patients ≥ 18 years of age [cockcroft 1976] normal electrocardiogram with qtcf of ≤ 450 ms

participation in any other clinical trial of an experimental treatment for covid-19 clinical signs indicative of severe or critical illness severity severe: any symptom of severe, systematic illness, including moderate illness, shortness of breath, or respiratory distress clinically suggestive of severe illness with covid-19, such as respiratory rate ≥ 30 breaths per minute, heart rate ≥ 125 per minute, saturation of oxygen (spo2) ≤ 93% on room air at sea level, or pao2/fio2 < 300 critical illness (one of the following): respiratory failure defined based on resource utilization requiring at least one of the following: endotracheal intubation and mechanical ventilation, oxygen delivered by high483 flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates > 20 l/min with fraction of delivered oxygen ≥ 0.5) noninvasive positive pressure ventilation, ecmo, or clinical diagnosis of respiratory failure (i.e., clinical need for one of the preceding therapies, but preceding therapies not able to be administered in setting of resource limitation) shock (defined by systolic blood pressure < 90 mm hg, or diastolic blood pressure < 60 mm hg or requiring vasopressors) multi-organ dysfunction/failure have a history of a positive sars-cov-2 serology test evidence of shock (defined by systolic blood pressure < 90 mm hg, or diastolic blood pressure < 60 mm hg or requiring vasopressors) patients who are hospitalized due to covid-19 patients who required oxygen therapy due to covid-19 patients who required mechanical ventilation or anticipated impending need for mechanical ventilation receiving v-v ecmo ≥ 5 days, or any duration of v-a ecmo have a history of convalescent covid-19 plasma treatment women who are pregnant or breastfeeding male or female of childbearing potential who has plans to become pregnant during the study period and for six months after the clinical study or who is not willing to take appropriate contraceptive measures (e.g., concomitant use of a spermicidal agent, barrier contraceptive, or/and intrauterine contraceptive) viral disease (hiv, hbv, hcv, etc.) other than covid-19 that are not adequately controlled or require administration of other antiviral agents or medications that could potentially interact with tb006 patients with a history or current evidence of any concomitant condition, therapy, or laboratory abnormality that, in the opinion of the investigator, might confound the results of the trial, interfere with the patient's participation and compliance

2

TrueBinding, Inc.

18

100

None

Mild/moderate disease at enrollment

2: Mild/moderate disease at enrollment

0

Treatment emergent adverse events

None

Phase 1

[{"arm_notes": "", "treatment_id": 1265, "treatment_name": "Tb006", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]